PI4K

Isoform-selective Products

PI4K Products

  • All (7)
  • PI4K Inhibitors (7)
  • New PI4K Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2728 AG-1478 AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
JCI Insight, 2023, 8(1)e163929
Toxins (Basel), 2023, 16(1)21
Mol Cell, 2022, 82(20):3919-3931.e7
S1489 PIK-93 PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM.
Cell Rep, 2023, 42(9):113035
ACS Chem Biol, 2022, 10.1021/acschembio.2c00052
BMC Biol, 2021, 19(1):194
S0041 UCB9608 UCB9608 (compound 44) is a potent, selective and orally bioavailable inhibitor of PI4KIIIβ with IC50 of 11 nM. UCB9608 is a potent immunosuppressive agent that improves metabolic stability and exhibits excellent pharmacokinetic profile.
E2981New PI4KIIIbeta-IN-10 PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 of 3.6 nM. It also exhibits weak inhibition of PI3KC2γ, PI3Kα, and PI4KIIIα, and <20% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ.
S6571 BQR695 BQR695 (NVP-BQR695) is a quinoxaline that displays sub-micromolar potency against human PI4KIIIβ (IC50~90 nM).
S6574 KDU691 KDU691 is a Plasmodium PI4K-specific inhibitor with IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively.
E2374 PI-273 PI-273, the first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM, can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.
S2728 AG-1478 AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
JCI Insight, 2023, 8(1)e163929
Toxins (Basel), 2023, 16(1)21
Mol Cell, 2022, 82(20):3919-3931.e7
S1489 PIK-93 PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM.
Cell Rep, 2023, 42(9):113035
ACS Chem Biol, 2022, 10.1021/acschembio.2c00052
BMC Biol, 2021, 19(1):194
S0041 UCB9608 UCB9608 (compound 44) is a potent, selective and orally bioavailable inhibitor of PI4KIIIβ with IC50 of 11 nM. UCB9608 is a potent immunosuppressive agent that improves metabolic stability and exhibits excellent pharmacokinetic profile.
E2981New PI4KIIIbeta-IN-10 PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 of 3.6 nM. It also exhibits weak inhibition of PI3KC2γ, PI3Kα, and PI4KIIIα, and <20% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ.
S6571 BQR695 BQR695 (NVP-BQR695) is a quinoxaline that displays sub-micromolar potency against human PI4KIIIβ (IC50~90 nM).
S6574 KDU691 KDU691 is a Plasmodium PI4K-specific inhibitor with IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively.
E2374 PI-273 PI-273, the first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM, can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.
E2981New PI4KIIIbeta-IN-10 PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 of 3.6 nM. It also exhibits weak inhibition of PI3KC2γ, PI3Kα, and PI4KIIIα, and <20% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ.

Choose Selective PI4K Inhibitors

Tags: PI4K Inhibitor | PI4K modulator | PI4K Inhibitors Review